Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. New therapy set to dominate the HIV market
  2. Experts call for a review of pharma manufacturing processes
  3. Marijuana: possible solution to the opioid crisis
  4. Adocia to begin trial of blood sugar regulation technology
  5. Incyte’s clinical trial flop indicates an uncertain future for IDO inhibitors

Latest Content

Marijuana: possible solution to the opioid crisis

In 2016, more than 110 people died every day due to opioid overdose in the US. The opioid crisis has reached epidemic levels, and the problem only seems to be growing. A solution to this epidemic is needed, and recent studies suggest that medicinal marijuana may provide some relief. Figure 1 presents the rate of opioid-related deaths in the US from 2007–2017.

Incyte’s clinical trial flop indicates an uncertain future for IDO inhibitors

An update on the KEYNOTE-252/ECHO-301 trial for Incyte/Merck’s Phase III drug combo in metastatic melanoma, epacadostat + Keytruda, rocked the biotech industry late last week. News that the once-hopeful drug combo did not meet one of its co-primary endpoints of progression free survival (PFS) sent stock prices for Incyte plummeting by 20%. Although many investors believe this knee-jerk reaction is unwarranted and temporary, it speaks to the importance of epacadostat, a first-in-class indoleamine 2,3-dioxygenase (IDO-1) inhibitor, in the small pharmaceutical company’s pipeline.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top